培美曲塞+顺铂与多西紫杉醇+替吉奥治疗晚期乳腺癌的效果比较

Effect comparison of Pemetrexed + Cisplatin and Docetaxel + Tegiol in the treatment of advanced breast cancer

目的比较培美曲塞+顺铂与多西紫杉醇+替吉奥治疗晚期乳腺癌的效果。方法回顾性分析我院2015年3月~2017年7月收治的、符合纳入标准的晚期乳腺癌患者80例。采用随机数字表法分为培美曲塞组(n=40)和多西紫杉醇组(n=40)。培美曲塞组予以培美曲塞+顺铂治疗;多西紫杉醇组给予多西紫杉醇+替吉奥治疗。分析两组患者的近期疗效、生存质量卡氏评分(KPS)评分及毒副作用情况。结果两组治疗后的KPS评分均较治疗前升高,差异有统计学意义(P<0.01);两组治疗后的KPS评分比较,差异无统计学意义(P>0.05)。两组的总有效率、疾病控制率比较,差异均无统计学意义(P>0.05)。两组毒副作用主要表现为骨髓抑制及胃肠道反应,经对症支持治疗后均可缓解。两组的骨髓抑制、胃肠道反应、脱发、皮疹的分级情况比较,差异均无统计学意义(Z=1.91、2.62、1.85、3.02,P>0.05)。结论培美曲塞+顺铂与多西紫杉醇+替吉奥治疗晚期乳腺癌的临床效果及安全性差异较小。临床可根据晚期乳腺癌患者的病情选择使用。

Objective To compare the effect of Pemetrexed + Cisplatin and Docetaxel + Tegiol in the treatment of advanced breast cancer.Methods All of 80 patients with breast cancer admitted to our hospital from March 2015 to July 2017 who met the inclusion criteria were retrospectively analyzed.The patients were divided into the Pemetrexed group (n=40) and Docetaxel group (n=40) according to the random number table method.Pemetrexed group was treated with Pemetrexed + Cisplatin,while Docetaxel group was treated with Docetaxel + Tegiol.The short-term efficacy,KPS score and adverse reactions in patients of the two groups were analyzed.Results Compared with before treatment,the KPS scores of both groups increased after treatment,and the differences were statistically significant (P<0.05).There was no significant difference in KPS score between the two groups after treatment (P>0.05).There were no significant differences in ORR and DCR between the two groups (P>0.05).The main adverse reactions of the two groups were bone marrow suppression and gastrointestinal tract reaction,which could be alleviated after symptomatic supportive treatment.There were no significant differences in bone marrow suppression,gastrointestinal reaction,alopecia and rash classification between the two groups (Z=1.91,2.62,1.85,3.02,P>0.05).Conclusion The clinical effect and safety of Pemetrexed + Cisplatin and Docetaxel + Tegiol in the treatment of advanced breast cancer have little difference.It can be selected according to the condition of breast cancer patients.